94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Paola Quaresima1
Samuel H. Myers2Basilio Pintaudi3,4
Rosario D’Anna3,5Michele Morelli6
Vittorio Unfer3,7*- 1Department of Obstetrics and Gynecology, Azienda Sanitaria Provinciale di Cosenza, Cosenza, Italy
- 2R&D Department, Lo.Li Pharma s.r.l, Rome, Italy
- 3The Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), Rome, Italy
- 4Azienda Socio Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 5Department of Human Pathology, University of Messina, Messina, Italy
- 6Department of Obstetrics and Gynecology, Annunziata Hospital, Cosenza, Italy
- 7UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy
A Corrigendum on
Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS
By Quaresima P, Myers SH, Pintaudi B, D’Anna R, Morelli M and Unfer V (2025) Front. Endocrinol. 16:1501110. doi: 10.3389/fendo.2025.1501110
In the published article, there was an error in Table 1 as published. The fasting glucose for IADPSG cut off was written as 95, this was a typo, as it should be 92. The correct table appears below.
Table 1
Table 1. Summary of diagnostic and screening criteria for GDM- adapted from Choudhury et al. (26).
In the published article, there was a typo in the text.
A correction has been made to Section 6.4, Paragraph 1. This sentence previously stated:
“In nature the two most common stereoisomers of inositol are myo-inositol (MI) and D-chiro-inositol, these molecules function as second messengers of various endocrine signals including follicle stimulating hormone (FSH), thyroid stimulating hormone (LH) and insulin (74).”
The corrected sentence appears below:
“In nature the two most common stereoisomers of inositol are myo-inositol (MI) and D-chiro-inositol, these molecules function as second messengers of various endocrine signals including follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH) and insulin (74).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: gestational diabetes mellitus, polycystic ovary syndrome, insulin, metformin, myo-inositol
Citation: Quaresima P, Myers SH, Pintaudi B, D’Anna R, Morelli M and Unfer V (2025) Corrigendum: Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS. Front. Endocrinol. 16:1569086. doi: 10.3389/fendo.2025.1569086
Received: 31 January 2025; Accepted: 14 February 2025;
Published: 26 February 2025.
Edited and Reviewed by:
Zhiqin Bu, Zhengzhou University, ChinaCopyright © 2025 Quaresima, Myers, Pintaudi, D’Anna, Morelli and Unfer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Vittorio Unfer, dnVuZmVyQGdtYWlsLmNvbQ==